{"filing":{"accession_number":"0001648257-26-000068","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-10-26","report_date":"2026-10-26","primary_document":"hcm-20261026x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000068/hcm-20261026x6k.htm"},"events":[{"id":37760,"run_id":34799,"accession_number":"0001648257-26-000068","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"HUTCHMED announced positive Phase III clinical trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in MET-driven EGFR-mutated NSCLC, demonstrating statistically significant improvements in progression-free survival (45% risk reduction, HR 0.55, p\u003c0.001) and overall survival (32% risk reduction, HR 0.68, p=0.010), with median OS extended by 4.9 months. Results were simultaneously published in The New England Journal of Medicine and presented at ESMO Congress 2026.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-10-26","form":"6-K","submitted_at":null,"items":[{"id":42583,"accession_number":"0001648257-26-000068","item_number":"EX-99.1","item_title":"hcm-ex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing positive Phase III clinical trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in treating MET-driven EGFR-mutated NSCLC. The disclosure reports statistically significant improvements in progression-free survival (45% risk reduction, HR 0.55, p\u003c0.001) and overall survival (32% risk reduction, HR 0.68, p=0.010), with median OS extended by 4.9 months. The results were simultaneously published in The New England Journal of Medicine and presented at ESMO Congress 2026. While technically a clinical milestone rather than financial earnings, this represents a material event affecting HUTCHMED's commercial prospects and pipeline value, warranting classification as an earnings_release analog for a biopharmaceutical company where clinical trial success is the primary value driver.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:23:45.734542+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":37761,"run_id":34799,"accession_number":"0001648257-26-000068","anchor_item_number":"EX-99.2","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"HUTCHMED announced positive Phase III clinical trial results (SANOVO trial) for ORPATHYS® plus TAGRISSO® in first-line EGFR-mutated lung cancer, showing 44% reduction in disease progression/death risk in the overall population and 55% in the high MET population, with median PFS of 24.9 months versus 13.8 months and median OS of 44.5 versus 34.9 months. Results were presented at ESMO Congress 2026.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-10-26","form":"6-K","submitted_at":null,"items":[{"id":42584,"accession_number":"0001648257-26-000068","item_number":"EX-99.2","item_title":"hcm-ex99d2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing positive Phase III clinical trial results for ORPATHYS® plus TAGRISSO® in first-line EGFR-mutated lung cancer (the SANOVO trial). The disclosure presents material clinical efficacy data—44% reduction in disease progression/death risk in the overall population and 55% in the high MET population, with median PFS of 24.9 months versus 13.8 months and encouraging OS benefit (median 44.5 versus 34.9 months)—presented at ESMO Congress 2026. While this is a clinical trial result rather than financial earnings, it is a material event disclosure of significant positive clinical data that would affect investor assessment of the company's pipeline and commercial prospects, warranting classification as an earnings_release analog (the closest fit for material event announcements in a 6-K context).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:23:45.734542+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42583,"accession_number":"0001648257-26-000068","item_number":"EX-99.1","item_title":"hcm-ex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing positive Phase III clinical trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in treating MET-driven EGFR-mutated NSCLC. The disclosure reports statistically significant improvements in progression-free survival (45% risk reduction, HR 0.55, p\u003c0.001) and overall survival (32% risk reduction, HR 0.68, p=0.010), with median OS extended by 4.9 months. The results were simultaneously published in The New England Journal of Medicine and presented at ESMO Congress 2026. While technically a clinical milestone rather than financial earnings, this represents a material event affecting HUTCHMED's commercial prospects and pipeline value, warranting classification as an earnings_release analog for a biopharmaceutical company where clinical trial success is the primary value driver.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:23:45.734542+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-10-26"},{"id":42584,"accession_number":"0001648257-26-000068","item_number":"EX-99.2","item_title":"hcm-ex99d2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing positive Phase III clinical trial results for ORPATHYS® plus TAGRISSO® in first-line EGFR-mutated lung cancer (the SANOVO trial). The disclosure presents material clinical efficacy data—44% reduction in disease progression/death risk in the overall population and 55% in the high MET population, with median PFS of 24.9 months versus 13.8 months and encouraging OS benefit (median 44.5 versus 34.9 months)—presented at ESMO Congress 2026. While this is a clinical trial result rather than financial earnings, it is a material event disclosure of significant positive clinical data that would affect investor assessment of the company's pipeline and commercial prospects, warranting classification as an earnings_release analog (the closest fit for material event announcements in a 6-K context).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:23:45.734542+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-10-26"}]}
